ArticleBMC cancer2018

Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.

Yukinori Ozaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.